Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 10/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PI4KA | P42356 | 1/20 | 0.51 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.51 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL10601870 | 0.94 | AHCY (0.55) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL4093935 | 0.82 | ADORA2A (0.64) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL30292318 | 0.82 | ADORA2A (0.64) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL2293264 | 0.82 | ADORA2A (0.68) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL10284145 | 0.81 | AHCY (0.60) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL14472999 | 0.81 | AHCY (0.60) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL13394191 | 0.80 | AHCY (0.79) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL14379019 | 0.80 | ADORA2A (0.60) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL11487766 | 0.78 | ADORA2A (0.71) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL2293269 | 0.78 | ADORA2A (0.66) | AHCYADORA2AADORA1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| EP-2001488-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | Alt Solutions, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007106561-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | ALT SOLUTIONS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| EP-0138656-B1 | CYCLIC PYROPHOSPHATES OF PURINE AND PYRIMIDINE ACYCLONUCLEOSIDES, THEIR PREPARATION AND THEIR APPLICATION IN ANTI-VIRAL COMPOSITIONS | MERCK & CO. INC. (US) | 1989-09-27 | — | — | EP | disclosed |
| US-4670424-A | Cyclic pyrophosphates of purine and pyrimidine acyclonucleosides | MERCK & CO., INC. (US) | 1987-06-02 | — | — | US | disclosed |
| EP-0138656-A1 | Cyclic pyrophosphates of purine and pyrimidine acyclonucleosides, their preparation and their application in anti-viral compositions | MERCK & CO. INC. (US) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | TERT, POLRMT, RNASE1 | AHCY 476/4885ADORA2A 1461/4885ADORA1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.